InVivo Therapeutics Holdings Announces New Appointment to Board of Directors

In Massachusetts, Hatfield previously also worked at Bristol-Myers Squibb (BMS). He earned an MBA from The Wharton School of the University of Pennsylvania and a Bachelor’s degree in pharmacy from Purdue University. He isn’t new to Board memberships, having served or currently serving on Boards for Ambit Biosciences and Biotechnology Industry Organization (BIO). Invivo focuses on treatment of spinal cord injuries using biomaterials and biotechnology, which is a good fit for Hatfield who told The Atlantic “I’m personally very motivated and excited by the company’s work, as I’ve had direct experience with a family member who suffered a serious spinal cord injury at an early age,” Hatfield said. “I’m hopeful that Mark and the InVivo team can make a meaningful difference to the lives of those suffering these kinds of traumatic injury.”